Last reviewed · How we verify

NCT06375213: INDE

Investigating Neurocognitive Disorders Epidemiology

Recruiting now Last updated 22 April 2024
What this trial tests

trial testing Plasma tau phosphorylated at Thr217 in Dementia in 990 participants. Currently enrolling.

Timeline
24 August 2023
Primary endpoint
24 August 2035
24 August 2035

Quick facts

Lead sponsorKing Chulalongkorn Memorial Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment990
Start date24 August 2023
Primary completion24 August 2035
Estimated completion24 August 2035
Sites1 location across Thailand

Drugs / interventions tested

Conditions studied

Sponsor

King Chulalongkorn Memorial Hospital

Who can join

35 and older, any sex, with Dementia or Cognitive Decline. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective cohort study with the main purpose of predicting progression neurocognitive disorders in Thai population. The main predictor variables to be evaluated are plasma phosphorylated tau (p-tau) level and cognitive test scores, which will be combined using statistical/computational modeling. Additionally, it seeks to evaluate biomarkers for diagnosing disease pathologies, understand their correlation with clinical outcomes, and explore the socioeconomic impact of neurocognitive disorders. The study invites both participants for biospecimen collection, structured interviews, and cognitive examinations and schedules follow-up visits annually or biennially.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Revisiting the therapeutic landscape of tauopathies: assessing the current pipeline and clinical trials.
    Harris GA, Hirschfeld LR, Gonzalez MI, Pritchard MC, et al · · 2025 · cited 8× · PMID 40462159 · DOI 10.1186/s13195-025-01775-x
  2. Exploring kidney function thereshole for plasma p‐tau 217 use
    Haethaisong T, Chongsuksantikul A, Oangkhana P, Luechaipanit W, et al · · 2025
  3. Performance of Cognitive Screening Tests for Alzheimer's Disease Pathology Defined by Plasma p‐tau217: A Prospective Cohort Study in Early Dementia Patients at King Chulalongkorn Memorial Hospital, Thailand
    Sarutikriangkri Y, Pongpitakmetha T, Hiransuthikul A, Rak‐areekul T, et al · · 2025
  4. The Impact of Physical Activity on Cognitive Function in Alzheimer's Disease Diagnosed with Plasma p‐tau 217 in Thailand, a middle income country: A Cross‐Sectional Study
    Rak‐areekul T, Chongsuksantikul A, Oangkhana P, Luechaipanit W, et al · · 2025
  5. The Effect of Social Determinants of Health on Cognitive Resilience to Alzheimer's Disease, Determined by Plasma p‐tau217 in the Prospective INDE Cohort in Thailand: A Story from a Middle‐Income Country
    Taweephol T, Pongpitakmetha T, Hiransuthikul A, Booncharoen K, et al · · 2025

Verify or expand the search:

Other recruiting trials for Dementia

Currently open trials in the same condition.

Other King Chulalongkorn Memorial Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06375213.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing